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Although the presence of tumor-infiltrating lymphocytes
(TILs) indicates an endogenous anti-tumor response,
immune regulatory pathways can subvert the effector
phase and enable tumor escape. Negative regulatory
pathways include expression of inhibitory receptors and
corresponding ligands, metabolic dysregulation, recruit-
ment of suppressive cell populations, and T cell-intrinsic
anergy. Recently, we have shown that the transcription
factor Egr2 is critical in controlling the anergic state
using an in vitro model system. Gene expression profil-
ing and Egr2 ChIP-Seq analysis revealed multiple Egr2-
driven cell surface proteins in T cell anergy, including
the inhibitory receptor Lag3, but also the costimulatory
receptor 4-1BB. We examined whether these surface
proteins might be useful for identifying the dysfunc-
tional tumor-reactive CD8+ T cells within the tumor
microenvironment. Flow cytometric analysis of TIL in
the B16, C1498, and MC57 tumor models revealed a
major population of CD8+ T cells expressing Lag3 along
with the defined inhibitory receptor PD-1. Approxi-
mately 43% of these cells expressed 4-1BB, and kinetic
analysis showed appearance of this population in the
tumor over time. Cell sorting revealed that the Lag3/
PD-1/4-1BB-triple positive cells showed the most severe
dysfunction as reflected by defective IL-2 production.
qRT-PCR confirmed expression of multiple anergy-asso-
ciated genes, including Egr2. Using an Egr2/IRES-GFP
knock-in mouse, Egr2GFPhigh TILS were confirmed to
show defective IL-2 production ex vivo. To examine
whether this CD8+ T cell population was likely to repre-
sent those recognizing specific antigens, TCR repertoire
analysis was performed and indicated TCRb skewing in
the marker positive population, indicating oligoclonality.
Analysis of CD8+ TIL specific for the model antigen SIY
confirmed that the vast majority of these cells expressed
Lag3, PD-1, and 4-1BB. Despite the inability to make
IL-2, the Lag3/PD-1/4-1BB-triple positive cells produced
high levels of IL-10, IFN-g, CCL1, and CCL22, arguing
that they might exert immunomodulatory functions and
not be completely inert. Indeed, an in vitro suppression
assay revealed that these cells are capable of inhibiting
proliferation of conventional T cells with a potency
similar to that seen with FoxP3+ regulatory T cells. Our
results suggest that the co-expression of Lag3, PD-1,
4-1BB, and perhaps Egr2 itself may identify a critical
subpopulation of dysfunctional TILs that are specific for
tumor antigens and contribute to an immune suppres-
sive tumor microenvironment. Ultimately, inhibiting or
agonizing receptors on this subpopulation could have
therapeutic relevance.
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